Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Study of Intratumoral Injection of LTX-315 in Combination With Pembrolizumab in Patients With Percutaneously Accessible Lesions With Advanced Melanoma Refractory to Pembrolizumab

Next Previous
X
Search
Trial Profile

A Phase II Study of Intratumoral Injection of LTX-315 in Combination With Pembrolizumab in Patients With Percutaneously Accessible Lesions With Advanced Melanoma Refractory to Pembrolizumab

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Jun 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pembrolizumab (Primary) ; Ruxotemitide (Primary)
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Acronyms ATLAS-IT-05
  • Sponsors Lytix Biopharma

    • Most Recent Events

    • 30 May 2024 According to a Lytix Biopharma media release, new update will be given during H2 2024.
    • 29 Feb 2024 Interim results from 20 melanoma patients, presented in a Lytix Biopharma media release.
    • 08 Nov 2023 According to a Lytix Biopharma media release, Later in the month, on 23 Nov, Dr Rekdal will give a presentation at the Redeye Life Science Day 2023 in Stockholm. There he will answer questions about the Company's latest positive developments, in particular, the preliminary Phase II data recently presented at ESMO.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top